Search

Your search keyword '"Tesar, Vladimir"' showing total 1,050 results

Search Constraints

Start Over You searched for: Author "Tesar, Vladimir" Remove constraint Author: "Tesar, Vladimir"
1,050 results on '"Tesar, Vladimir"'

Search Results

4. National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas.

5. Inequities in kidney health and kidney care

7. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

8. Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis

15. Availability, coverage, and scope of health information systems for kidney care across world countries and regions.

16. The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials

17. Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey.

18. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

19. Peritoneal Dialysis Use and Practice Patterns: An International Survey Study

20. Hemodialysis Use and Practice Patterns: An International Survey Study

23. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

25. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

26. Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions

27. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

28. #812 Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis

29. #123 Impact of atacicept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study

32. WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY

34. Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis

37. WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY

39. Increasing access to integrated ESKD care as part of universal health coverage

40. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

41. Early Identification of CKD—A Scoping Review of the Global Populations

44. Nephrology in the Czech Republic

46. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

47. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

48. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy

49. Rituximab in Membranous Nephropathy

50. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients

Catalog

Books, media, physical & digital resources